As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are increasing the number and types of collaborative relationships they are forming with other developers.
As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are increasing the number and types of collaborative relationships they are forming with other developers, as well as with service providers and other stakeholders, according to the Tufts Center for the Study of Drug Development.
R&D leaders from the pharmaceutical and biotech industry, who recently participated in a roundtable discussion hosted by Tufts CSDD, said that well-structured collaborative agreements, in which the parties agree to share risks and rewards, can increase the possibility that a new medicine, which otherwise might not get to market, wins regulatory approval - and at lower cost.
"The significance of these relationships involving drug sponsors, developers, and external service providers is that they become stakeholders in each other's business-not just customers and vendors-who stand to gain, or lose, together," said Tufts CSDD Director Kenneth I Kaitin.
According to Tufts CSDD, more than half of all new drugs approved in the United States between 2000 and 2011 were developed by companies that collaborated in one form or another with other entities.
Other points discussed at the roundtable, summarized in the August Tufts CSDD R&D Management Report, released today, include the following:
Upcoming Tufts CSDD Executive Forum Roundtable meetings:
Sept. 18, 2014: New Directions in Outsourcing
November 6, 2014: Managing the Changing Investigative Site Landscape
March 5, 2015: FDA's Breakthrough Therapy Designation - A Three-Year Assessment
May 14, 2015: Diagnostic-Therapeutic Co-development Strategies and Best Practices
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.